Research ... For the Future

Len Lichtenfeld, MD, MACP
Interim Chief Medical and Scientific Officer
OUR MISSION IS TO

SAVE LIVES,

CELEBRATE LIVES,

&

LEAD THE FIGHT

FOR A WORLD WITHOUT CANCER.
ATTACKING CANCER FROM EVERY ANGLE

We are Activists
Convening relentless partners for awareness and impact
- ACS CAN
- Cancer Control Roundtables
- Coaches vs. Cancer
- CEOs Against Cancer
- Corporate partnerships
- Health Systems partnerships

We build Communities
United to fight cancer with access to treatment and compassion
- Hope Lodge
- Road To Recovery
- CHANGE Grants
- Relay For Life and Making Strides
- Galas and golf events

We deliver Breakthroughs
Investing in innovative research to develop game-changing approaches
- Extramural research grants
- Cancer Prevention Studies
- ACS journals and publications
- Behavioral Research Center
- ACS BrightEdge Ventures

We provide Direction
A passionate ally, empowering people with information & answers
- NCIC
- Patient Navigation Program
cancer.org
- Cancer screening guidelines
- Health professional and patient education
CANCER PREVENTION STUDIES (CPS)

Intramural Research

**Smoking**

Our early studies linking smoking with lung cancer and higher overall death rates played an important role in The Surgeon General’s landmark 1964 report showing that smoking causes lung cancer.

**Obesity**

CPS-I revealed the first epidemiologic evidence that obesity increases risk of premature death, and CPS-II established the link between obesity and death from breast, colorectal, and other cancers.

**Aspirin**

CPS-II was the first prospective study to find a link between regular aspirin use and lower risk of colorectal cancer, opening the door to more research on aspirin and risk of other cancers.

**Diet & Exercise**

Our studies revealed that high intake of red and processed meats and alcohol, low physical activity, and longer sitting time increase risk of cancer or mortality.

**Genetics**

CPS-II data and biospecimens have been included in the identification or validation of nearly every confirmed breast, prostate, and pancreatic cancer genetic susceptibility variant known to date.
ACS AND EXTRAMURAL RESEARCH

Long-term commitment, strategic investments, successful outcomes

ACS IS THE LARGEST NON-GOVERNMENTAL FUNDER OF CANCER RESEARCH IN THE U.S.

• Over $4.8B in research funded since 1946
• Very often first major grant for young researchers
• 70% of grant recipients will obtain NIH funding
• 47 Nobel Laureates funded prior to their award
• 70% of NCI Cancer Center Directors

>33,00 GRANTS
>24,000 INVESTIGATORS
>1,100 INSTITUTIONS
### 2017 FUNDING BY SELECTED CANCER TYPES

**Total Awarded: $98.4 million**

<table>
<thead>
<tr>
<th>Cancer Type</th>
<th>Awarded Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>BREAST CANCER</td>
<td>$12.4 million</td>
</tr>
<tr>
<td>COLON AND RECTAL CANCER</td>
<td>$9.2 million</td>
</tr>
<tr>
<td>LUNG CANCER</td>
<td>$8.1 million</td>
</tr>
<tr>
<td>LEUKEMIA</td>
<td>$6.2 million</td>
</tr>
<tr>
<td>PROSTATE CANCER</td>
<td>$6 million</td>
</tr>
<tr>
<td>PANCREATIC CANCER</td>
<td>$4.9 million</td>
</tr>
<tr>
<td>SKIN CANCER</td>
<td>$4.1 million</td>
</tr>
<tr>
<td>OVARIAN CANCER</td>
<td>$2.4 million</td>
</tr>
<tr>
<td>BLOOD CANCER</td>
<td>$2 million</td>
</tr>
<tr>
<td>BRAIN TUMOR</td>
<td>$1.9 million</td>
</tr>
<tr>
<td>LIVER CANCER</td>
<td>$1.9 million</td>
</tr>
<tr>
<td>HEAD AND NECK CANCER</td>
<td>$1.1 million</td>
</tr>
<tr>
<td>BLADDER CANCER</td>
<td>$1 million</td>
</tr>
<tr>
<td>MYELOMA</td>
<td>$0.43 million</td>
</tr>
<tr>
<td>OTHER CANCER TYPES*</td>
<td>$8 million</td>
</tr>
</tbody>
</table>

*Other Cancer Types apply to all cancers $25.1M
CANCER RESEARCH INVESTMENT PLATFORM

New Framework

Launch
Launch careers of most innovative young cancer scientists in the U.S.
• Top 10-15% of scientists selected by rigorous, competitive, and independent peer review
• Breakthroughs in foundational cancer research on cause, prevention, detection, treatment and survivorship
• Investment to change the future of cancer

Boost
More focused approach on providing support for projects to catapult the foundational research to the next level
• Any aspect of bench to bedside to community research continuum
• Mission Boost – patient/population focused work
• Discovery Boost – all other cancer research
• Can be individual awards or teams assembled around ACS Professors

Accelerate
Fund companies with the most promising cancer solutions: (diagnostics, therapeutics, devices, technologies & service)
• ACS BrightEdge Ventures initiative to invest for-profit companies with today’s solutions
• Accelerate commercial adoption to allow for patients to receive access to novel and innovative solutions at scale
• Will underwrite for mission and returns
MISSION BOOST GRANTS

REINVEST IN ACS GRANTEES WITH ‘BOOST’ RESOURCES FOR HIGHLY INNOVATIVE PROJECTS TO ACCELERATE CLINICAL IMPACT.

• Current or past ACS grantees propose high risk/ high reward projects in two stages:

  1. Stage 1: Project that enables the study of a new drug, device, or procedure in patients. 24 months / $240,000
  2. Stage 2: Second grant awarded if initial project milestones are reached. 18 months / $360,000
• TheoryLab is an online community exclusively for current and former American Cancer Society grantees, mentors, reviewers, and stakeholders
• Two guiding principles: creativity and innovation
• Created to inspire transdisciplinary collaborations to define and investigate the most exciting cancer research opportunities
PARTNERSHIPS

MELANOMA RESEARCH ALLIANCE
• Adverse Events Associated with Immune Therapy
• Metastasis

GLOBAL CENTER FOR MEDICAL INNOVATION
• Mission Boost Projects – Medical Devices

ST. BALDRICK’S FOUNDATION
• Innovative Projects in the Context of Clinical Trials

5-6 OTHERS IN ACTIVE CONVERSATIONS OR NEGOTIATIONS
CANCER RESEARCH INVESTMENT PLATFORM

Advances in Biotech are Creating New Opportunities to Fund Technology and Therapeutic Companies

AMERICAN CANCER SOCIETY RESEARCH
*Investing in today’s problems for tomorrow solutions*

**Launch**
Invests in the future of cancer research

*Focus:
The best and brightest in basic science*

**Boost**
Brings innovation closer to commercialization by exploring applications

*Focus:
Bringing discoveries closer to commercialization*

**Accelerate**
Targets most promising companies in oncology

*Focus:
Early- to late-stage companies*

BRIGHTEDGE
*Investing in today’s solutions*
• Charitably funded cancer-specific impact fund
• Evergreen, perpetual fund model, with all proceeds from liquidity events reinvested into the Society’s life-saving work
• Impact Donors will receive institutional quality quarterly reports, visibility into our network and deal flow pipeline
• Every donated dollar attributed to individual donors for transparency, with visibility to fund performance and compounding effect generated from returns
• Professionally managed, with annual Impact Donor Conference to meet our company CEOs, hear from members of our investor and clinical advisory boards and network with other philanthropically minded donors
THANK YOU

Len Lichtenfeld, MD, MACP
Interim Chief Medical and Scientific Officer
Len.Lichtenfeld@cancer.org